New immune cells targeting advanced kidney cancer after standard treatments fail

Plain-English translation of NCT07551349 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated June 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing a new treatment called dual-target CD70/CAIX CAR-NK cells for people with advanced clear cell renal cell carcinoma (kidney cancer) that has not responded to standard treatments. The treatment uses specially engineered immune cells from donated cord blood that are designed to recognize and attack kidney cancer cells. The goal is to see if this medication can help shrink tumors and improve outcomes in people whose cancer has stopped responding to other therapies.

Advanced kidney cancer remains very difficult to treat once it progresses past current standard medications like immunotherapy and VEGF-pathway drugs. This trial exists to test whether this new medication—which uses a different approach with engineered natural killer cells—might offer hope to patients who have fewer effective options left.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced or metastatic clear cell kidney cancer that has grown despite previous standard treatments
you have previously received at least one immunotherapy drug and at least one VEGF-targeted drug, or you cannot tolerate these standard options
your tumor tissue shows the specific markers (CD70 and/or CAIX) that this treatment is designed to target
you are at least 18 years old and in good enough overall health to receive this treatment
you have at least one measurable tumor lesion that can be tracked on imaging scans

You likely don't qualify if…

you have active, untreated brain cancer or cancer that has spread to the brain lining (leptomeningeal disease)
you have received other engineered cell therapies (such as CAR-T or CAR-NK) within a certain time window before this trial
you have significant liver or bile duct disease, such as cirrhosis or active biliary obstruction
you have an active infection you cannot control, including HIV, hepatitis B or C, or tuberculosis
you are pregnant, breastfeeding, or have another active cancer requiring treatment

What participation looks like

You will receive chemotherapy drugs ( and cyclophosphamide) to prepare your body, then receive an infusion of the engineered immune cells on Day 0. You may be eligible for a second infusion on Day 15 if you tolerate the first treatment well. Throughout the trial, you will have frequent medical visits, blood tests, and imaging scans to monitor how you respond and check for side effects. The trial includes special liver function monitoring because of potential risks related to how the treatment affects liver tissue.

AI-generated summary from trial data · Jun 4, 2026 · Not medical advice

Trial locations(1 site)

China

Peking University Shenzhen Hospital, Shenzhen, Guangdong